

CURRICULUM VITAE

Stephen M. Roberts, Ph.D.

Center for Environmental & Human Toxicology
University of Florida
Box 110885
Bldg. 471, Mowry Road
Gainesville, Florida 32611-0885
(352) 294-4514 FAX: (352) 392-4707
e-mail: smroberts@ufl.edu

ACADEMIC APPOINTMENTS

Director, Center for Environmental & Human Toxicology
(1995- present)
Professor, (1999-present); Associate Professor (1993-1999); Assistant
Professor (1990 - 1993)
Department of Physiological Sciences, College of Veterinary Medicine
(1990 – present); Department of Pharmacology & Therapeutics, College of
Medicine (1990 – present); Department of Environmental and Global
Health, College of Public Health and Health Professions (2009 – present)
University of Florida, Gainesville, FL

Assistant Professor of Toxicology (1986 - 1989)
Department of Pharmacology and Interdisciplinary Toxicology
College of Medicine
University of Arkansas for Medical Sciences, Little Rock, AR

Assistant Professor of Pharmacology & Toxicology (1980 - 1986)
Adjunct Asst. Prof. of Pharmacology & Toxicology (1986 - 1989)
Division of Pharmacology & Medicinal Chemistry
College of Pharmacy
University of Cincinnati Medical Center, Cincinnati, OH

EDUCATION AND TRAINING

B.S. Pharmacy (1973), College of Pharmacy, Oregon State University,
Corvallis, OR

Ph.D. (1977), Department of Pharmacology, College of Medicine,
University of Utah, Salt Lake City, UT

NIH Post-doctoral Fellow (1977-1980), Department of Pharmaceutics,
School of Pharmacy, State University of New York at Buffalo, Amherst, NY

PROFESSIONAL RECOGNITION

Fellow, Academy of Toxicological Sciences, 2007 – present.

University of Florida Research Foundation Professorship, 2001

Pfizer Award for Research Excellence, University of Florida College of
Veterinary Medicine, 1998

PROFESSIONAL SOCIETY MEMBERSHIP

Society of Toxicology
Society for Risk Analysis
American Society for Pharmacology and Experimental Therapeutics

FEDERAL ADVISORY
COMMITTEE SERVICE

Member, Chemical Assessment Advisory Committee, Science Advisory Board, U.S. Environmental Protection Agency, 2012 – present.

Member, Science Advisory Board (Chartered), U.S. Environmental Protection Agency, 2006 – 2013

Chair, Technical Reports Peer Review Panel, National Toxicology Program, U.S. Department of Health and Human Services, January, 2012.

Member, Science Advisory Board, National Center for Toxicological Research, U.S. Food and Drug Administration, 2006 – 2010

Permanent Panel Member, FIFRA Scientific Advisory Panel, U.S. Environmental Protection Agency, 1999 – 2005; Chair, 2002 – 2005

Member, Board of Scientific Counselors, National Toxicology Program, U.S. Department of Health and Human Services, 2002 – 2005

Chair, Nanotechnology Working Group, National Toxicology Program, U.S. Department of Health and Human Services, 2005 – 2006.

PROFESSIONAL
JOURNAL SERVICE

Associate Editor, *Nanotoxicology* (2009 – present)

Associate Editor for Debates/Commentaries, *Human and Ecological Risk Assessment*, 1997-2004.

Editorial Advisory Board:

- *Toxicology and Applied Toxicology*, 1997- present
- *Nanotoxicology*, 2006- present
- *Human and Ecological Risk Assessment*, 2004 – 2013
- *Dose-Response*, 2003 – 2012

Reviewer for: *Toxicology and Applied Pharmacology*, *Journal of Pharmacology & Experimental Therapeutics*, *Biochemical Pharmacology*, *Journal of Pharmaceutics*, *Life Sciences*, *Drug Metabolism and Disposition*, *Cells Stress and Chaperones*, *Environmental Science and Technology*, *Human and Ecological Risk Assessment*, *Toxicology Letters*, *Journal of Toxicology and Environmental Health*, *Proceedings of the Society for Experimental Biology and Medicine*, *Toxicological Sciences*, *Risk Analysis*, *Hepatology*, and *International Journal of Cancer*, *Journal of Hazardous Materials*, *Chemosphere*, *European Child and Adolescent Psychiatry*, *Nature Nanotechnology*, *Regulatory Toxicology and Pharmacology*, *Medical Science Monitor*, *Archives of Medicine*, *Clinical and Experimental Pharmacology and Physiology*.

OTHER PROFESSIONAL
ACTIVITIES

Chair, Interdisciplinary Toxicology Graduate Committee, University of Florida, 1992- present

Faculty Advisory Council, School of Natural Resources and the Environment, 2004 – present

Member, Committee on the Review of the Styrene Assessment in the National Toxicology Program 12th Report on Carcinogens, National Research Council, 2013 – present

Member, Advisory Panel, Food Additives Project, Pew Charitable Trusts, 2010-present

Secretary-Treasurer, Nanotoxicology Specialty Section, Society of Toxicology, 2009 – 2010

Core Faculty, Masters of Science in Clinical Investigation, University of Florida College of Medicine, 1999 – 2009

OTHER PROFESSIONAL
ACTIVITIES (continued)

Executive Committee, Masters in Public Health Program, University of Florida College of Public Health and Health Professions, 2004 – 2008

Chair, Medical-Scientific Advisory Board, University of Florida Tissue Bank, 1996-1998

Member, Committee on the Bioavailability of Contaminants in Soils and Sediments, National Research Council, 2000 – 2003

Chair, Florida Risk-Based Priority Council, 1995 - 1996

Member of Placement Committee, Society of Toxicology, 1993-1995

Member, Oral Bioavailability Scientific Review Committee, Department of Environmental Quality, State of Michigan, 2002-2003.

Chairman or Co-Chairman for scientific sessions at the annual meeting of the Society of Toxicology: "Reactive Intermediates" (1991), "Chemical Interactions and Mixtures" (1992), "Glutathione: Modulator of Toxicity" (1993), "Response of the Liver to Toxic Agents" (1994), "Reactive Intermediates" (1998), "Metals Toxicology" (2006).

Grant Review: Safety and Occupational Health Study Section, NIOSH, 1988; USEPA ORD Exploratory Research Program - Human Health, 1998; Fogarty International Center, NIH, 2001; Air Force Office of Sponsored Research, 2004; NIH Special Emphasis Panel, Nanomedicine Development Centers, 2005, 2006.

EXTRAMURAL GRANTS
AND CONTRACTS,
BASIC RESEARCH AND
TRAINING

National Institute for Environmental Health Sciences, R01 ES05216
Stress and Environmental Chemical Hazards.

1/1/89 - 12/31/93; \$431,593 total direct costs.

Role: Co-Investigator (R. James, P.I.)

National Institute on Drug Abuse, R01 DA06601

Substance Abuse Potentiation of Cocaine Hepatotoxicity.

9/30/89 - 8/15/92; \$85,964 total direct costs.

8/15/92 - 8/14/95; \$214,139 total direct costs (Renewal)

8/01/95 - 6/30/98; \$304,133 total direct costs. (Renewal)

Role: Principal Investigator

National Institute on Drug Abuse, R01 DA06893

Methamphetamine Potentiated Hepatotoxicity.

9/30/91 - 8/31/94; \$228,334 total direct costs.

Role: Principal Investigator

National Institute for Environmental Health Sciences, R01 ES07213

Heat Shock in Toxicity Assays

8/1/94 - 7/31/97; \$470,323 total direct costs.

12/01/98 – 11/30/01; \$584,404 total direct costs (Renewal)

Role: Co-Principal Investigator

National Institute on Drug Abuse, F32 DA05565

NRSA for Sandra Rousseau, D.V.M.

12/31/93 - 12/31/96; \$104,400 total direct costs.

Role: Sponsor

National Institute for Environmental Health Sciences, P42 ES07375

Health Effects of Chlorinated Compounds

05/01/95 - 03/31/00; \$2,616,685 total direct costs.

04/01/00 – 03/31/05; \$8,891,632 total direct costs (Renewal)

Role: Program Project Co-Principal Investigator

EXTRAMURAL GRANTS
AND CONTRACTS,
BASIC RESEARCH AND
TRAINING (continued)

Florida Department of Environmental Protection
Arsenic Bioavailability in a Primate Model
08/04/98 – 12/01/00; \$250,000 total costs
Role: Principal Investigator

National Institutes of Health
Research Experience for Veterinary Medical Students
07/03/03 – 04/30/06; \$292,140
Role: Co-Investigator

Exponent
Oral Bioavailability of Arsenic from Soil in Primates
07/16/01 – 06/30/04; \$120,420 direct costs
Role: Principal Investigator

U.S. Air Force
Dermal Penetration of Nanoscale High Energetic Materials
07/03 – 03/04; \$25,000 total costs
Role: Principal Investigator

National Cancer Institute, R01 CA903489
Prevention of Chemotherapy-Induced Hair Loss
07/01/03 – 06/30/07; \$600,750
Role: Co-Principal Investigator

HSF Pharmaceuticals
Construction of a Recombinant HSV Vector
05/01/07 – 04/30/08; \$12,500
Role: Principal Investigator

U.S. Environmental Protection Agency
Assessment of Arsenic Bioavailability from Soil in Cynomolgus Monkeys
11/01/07 – 05/30/09; \$196,750 total costs.
Role: Principal Investigator

State of Florida, Centers of Excellence
Center for Nanobiosensors
07/07 – 06/11; \$4,200,000 total direct costs
Role: Principal Investigator of Biocompatibility Project

Gulf Power
Assessment of Arsenic Bioavailability from Soil in Non-Human Primates
09/01/10 – 12/31/13; \$160,000 total costs
Role: Principal Investigator

HSF Pharmaceuticals
Evaluation of Heat/Heat-and Heat-Activated, Oncolytic Virus-Based Tumor Vaccines
06/30/10 – 06/30/13; \$25,000 total costs
Role: Principal Investigator

Strategic Environmental Research and Development Program, DoD
PAH Interactions with Soil and Effects on Bioaccessibility and Bioavailability to Humans
10/01/10 – 09/30/13; \$300,000 subcontract
Role: Subcontract Principal Investigator

NIEHS
Seafood Hydrocarbon Residues and Coastal Community Health Risks
07/01/11-06/30/2016; \$6,546,000
Role: Project 3 Co-PI

EXTRAMURAL GRANTS
AND CONTRACTS,
APPLIED TOXICOLOGY
& RISK ASSESSMENT

Florida Department of Environmental Protection, WM-530
Toxicology Support Services
10/1/93 - 9/30/95; \$230,000 total costs.
Role: Contract Co-Manager

Florida Center for Solid and Hazardous Waste Management
Review of Available Methodologies for Evaluating the Potential Human Health and Environmental Impacts of a Hazardous Waste Incinerator.
7/1/94 - 11/30/95; \$42,671 total direct costs.
Role: Project Manager

Florida Department of Environmental Protection
Toxicology Support Services
11/14/95 - 9/30/97 (WM-617); \$340,000 total costs
11/21/97 - 9/7/00 (WM-696); \$462,800 total costs
8/31/00 – 6/30/02 (HW-447); \$460,000 total costs
9/5/02 – 6/30/04 (HW-492); \$520,000 total costs
7/1/04 – 6/30/10 (HW-520); \$1,415,200 total costs
7/1/04 – 6/30/10 (HW-521); \$509,600 total costs
7/1/10 – 6/30/11 (HW-548); \$285, 400 total costs
7/1/10 - 6/30/11 (HW-549); \$94,000 total costs
7/1/11 – 6/30/12 (HW-548); \$282,000 total costs
7/1/11 – 6/30/12 (HW-549); \$89,000 total costs
7/1/12 – 6/30/13 (HW-548); \$176,000 total costs
7/1/12 – 6/30/13 (HW-549); \$77,000 total costs
Role: Contract Manager

Florida Department of Environmental Protection
Fixed Laboratory Response Capability for the Florida Department of Environmental Protection, Bureau of Laboratories
09/10/08 – 06/09/09; \$76,992
Role: Contract Manager

Florida Department of Environmental Protection
Development of ERLN Health and Safety Plan and Training
06/19/09 – 06/30/10; \$25,000
Role: Contract Manager

Florida Department of Health
Environmental Toxicology Consulting Services in Support of Mission 432, ESF8, Deep Water Horizon
07/09/10 – 09/30/10; \$51,064
Role: Contract Co-Manager

TEACHING

General Toxicology (VME 6602). A graduate-level course covering the general principles of toxicology and mechanisms by which toxic effects are produced in target organs and tissues. 3 gr. credit course. (1991- present)

Toxic Substances (VME 6605). A graduate-level course covering signs and symptoms, diagnosis and clinical management, and mechanisms of toxicity of major classes of toxicants. 3 gr. credit course. (2000 – present)

Human Health Risk Assessment (VME 6607). A graduate-level course dealing with the fundamental concepts, techniques, and issues associated with human health and ecological risk assessment. 3 gr. credit course. (1997- present)

Advanced Toxicology (VME 6603). A graduate-level course providing a survey of the health effects of each of the major classes of toxicants. Course coordinator. 3 gr. credit course. (1992-1998).

Issues in the Responsible Conduct of Research (VME 6767). A graduate-level course addressing laws, policies, guidelines and principles concerning the conduct of research in an ethical manner. Course coordinator. 1 gr. credit course (1994 - 2002).

Also, lectures on principles of toxicology to medical students in *Phase B Pharmacology* (BMS 5404), physician assistant students in *Pharmacotherapeutics for PAs* (PAS3023), pharmacology graduate students in *Principles of Pharmacology* (GMS 7593), and law students in *Environmental Issues* (LAW 6477).

GRADUATE STUDENTS

Student	Role/Degree/Date
Georgia Hinkley	supervisory professor, Ph.D. current
Matthieu Miller	supervisory professor, Ph.D. current
Kevin Kirchner	supervisory professor, Ph.D. student
Fei Wang	supervisory professor, Ph.D. awarded 2005
J. Keith Tolson	supervisory professor, Ph.D. awarded 2004
William Salminen	supervisory professor, Ph.D. awarded 1997
MaryLynn Cook	supervisory professor, Ph.D. awarded 1996
Greg Hanley, D.V.M.	co-supervisory professor, Ph.D. awarded 1998
Michele Mautino, D.V.M.	supervisory professor, Ph.D. awarded 1993
Nicholas P. Skoulis	supervisory professor, Ph.D. awarded 1988
Hank F. Simmons, M.D.	supervisory professor, Ph.D. awarded 1988
Robert A. Budinsky	supervisory professor, Ph.D. awarded 1986
Ed McCray	supervisory professor, M.S. awarded 1989
Candice Lavelle	dissertation committee, Ph.D. current
Ahmed Alalaiwe	dissertation committee, Ph.D. current
Erica Anderson	dissertation committee, Ph.D. current
Paul Carpinone	dissertation committee, Ph.D. awarded 2012
Charles Jenkins	dissertation committee, Ph.D. awarded 2012
Ramona Smith-Burrell	dissertation committee, Ph.D. awarded 2012
Kerry Seibein	dissertation committee, Ph.D. awarded 2011
Debamitra Dutta	dissertation committee, Ph.D. awarded 2009
Scott Wasdo	dissertation committee, Ph.D. awarded 2005
Heath Rauschenberger	dissertation committee, Ph.D. awarded 2004

Michele McGarry	dissertation committee, Ph.D. awarded 2001
Chris Bowman	dissertation committee, Ph.D. awarded 2001
Zhen Lou	dissertation committee, Ph.D. awarded 2001
Luke Utley	dissertation committee, Ph.D. awarded 2001
Steve Davis	dissertation committee, Ph.D. awarded 2000
Marisol Sepulveda, D.V.M.	dissertation committee, Ph.D. awarded 2000
Rachel Cornett	dissertation committee, Ph.D. awarded 2000
Susan Loerzel	dissertation committee, Ph.D. awarded 1999
Peter LaPuma	dissertation committee, Ph.D. awarded 1998
Zeen Tong	dissertation committee, Ph.D. awarded 1996
Scott Masten	dissertation committee, Ph.D. awarded 1998
Mary Alice Smith	dissertation committee, Ph.D. awarded 1990
Neil Pumford	dissertation committee, Ph.D. awarded 1989
Brent D. Kerger	dissertation committee, Ph.D. awarded 1988
Glenn C. Millner	dissertation committee, Ph.D. awarded 1988
M. Ann Clevenger	dissertation committee, Ph.D. awarded 1987
David Stong	dissertation committee, Ph.D. awarded 1984
Gabriel Shook	thesis committee, M.S. awarded 2011
Alex McNally	thesis committee, MS. awarded 2004
Kristen Henson, D.V.M.	thesis committee, M.S. awarded 2000
Nicole Ushakoff Jurczyk	thesis committee, M.S. awarded 1993
Lisa Barfield	thesis committee, M.S. awarded 1990
Scott Miselnicky	thesis committee, M.S. awarded 1987
Art Wesselman	thesis committee, M.S. awarded 1986

POSTDOCTORAL FELLOWS in BASIC RESEARCH

Name, Dates	Dates:
Florence Ndikum-Moffor, Ph.D.	1996-1999
Scott Wasdo, Ph.D.	2006 - 2008
Fei Wang, Ph.D.	2006

POSTDOCTORAL FELLOWS in RISK ASSESSMENT

Name, Dates	Dates:
Chris Borgert, Ph.D.	1992- 1994
Robert DeMott	1993-1995
Lisa Tonner-Navarro, Ph.D.	1996-1998
N. Christine Halmes, Ph.D.	1997-1999
Christopher Saranko, Ph.D.	1998- 2000
Kristen Jordan, Ph.D.	2000- 2001
Hugo Ochoa, D.V.M., Ph.D.	2000- 2003
Bernard Gadagbui, Ph.D.	2001-2003
Shukla Roy, Ph.D.	2001-2004
Gary Barbee, Ph.D.	2004
Jessica Noggle, Ph.D.	2005
Leah Stuchal, Ph.D.	2005- 2008
Kendra Goff, Ph.D.	2007 -2008
Michael Miyittah, Ph.D.	2009 – 2010
Roxana Weil	2012 -present

PUBLISHED MANUSCRIPTS:

1. Roberts SM, Franklin MR, Snyder EW, and Beck EC: Effects of chronic oral methadone on hepatic microsomal drug metabolism in monkeys. *Toxicol. Appl. Pharmacol.* 42: 607-612, 1977.
2. McCloskey KL, Garriot JC, and Roberts SM: Quinine concentrations in blood following the consumption of gin and tonic preparations in a social setting. *J. Analytical Tox.* 2:110-112, 1978.
3. Soles C, Giacomini KM, Roberts SM, and Giacomini JC: A convenient method for repetitive blood sampling in the dog. *J. Pharmacol. Methods* 1:259-261, 1978.
4. Roberts SM and Franklin MR: Modification of hepatic microsomal oxidative drug metabolism in rats by the opiate maintenance drugs acetylmethadol, propoxyphene, and methadone. *Life Sci.* 25: 845-852, 1979.
5. Roberts SM and Levy G: Pharmacokinetic studies of propoxyphene IV: Effect of renal failure on systemic clearance in rats. *J. Pharm. Sci.* 69:363-364, 1980.
6. Giacomini KM, Roberts SM, and Levy G: Evaluation of methods for producing renal dysfunction in rats. *J. Pharm. Sci.* 70:117-121, 1981.
7. Pond SM, Kaysen GA, Menke DJ, Galinsky RE, Roberts SM and Levy G: Massive intoxication with acetaminophen and propoxyphene: Unexpected survival and unusual pharmacokinetics of acetaminophen. *Clin. Tox.* 19:1-16, 1982.
8. James RC, Roberts SM, and Harbison RD: The perturbation of hepatic glutathione by α_2 -adrenergic agonists. *Fund. Appl. Tox.* 3:303-308, 1983.
9. Roberts SM, Budinsky RA, Adams LE, Litwin A, and Hess EV: Procainamide acetylation in strains of rat and mouse. *Drug Metab. Dispos.* 13:517-519, 1985.
10. Budinsky RA, Roberts SM, Coats EA, Adams LE, and Hess EV: The formation of procainamide hydroxylamine by rat and human microsomes. *Drug Metab. Dispos.* 15:37-43, 1987.
11. Roberts SM, Grund VR, James RC, and Harbison RD: Histamine and hepatic glutathione in the mouse. *Life Sci.* 40:2103-2110, 1987
12. James RC, Schiefer MA, Roberts SM, and Harbison RD: Antagonism of cocaine-induced hepatotoxicity by the α -adrenergic antagonists phentolamine and yohimbine. *J. Pharmacol. Exp. Ther.* 242:726-732, 1987.
13. Roberts SM, Skoulis NP, and James RC: A centrally-mediated effect of morphine to diminish hepatocellular glutathione. *Biochem. Pharmacol.* 36:3001-3005, 1987.
14. Roberts SM, James RC, Simmons HF, and Harbison RD: Alcohol and cocaine-induced liver injury. *Alcohol Health & Res. World* 11:20-25, 1987.
15. Kerger BD, James RC, and Roberts SM: An assay for phentolamine using high performance liquid chromatography with electrochemical detection. *Anal. Biochem.* 170:145-151, 1988
16. Smith AC, Roberts SM, Berman LM, Harbison RD, and James RC: Effects of piperonyl butoxide on halothane hepatotoxicity and metabolism in the hyperthyroid rat. *Toxicology* 50:95-105, 1988.

17. Kerger BD, Gandy J, Bucci TJ, Roberts SM, Harbison RD, and James RC: Antagonism of bromobenzene-induced hepatotoxicity by the alpha adrenergic blocking agents, phentolamine and idazoxan. *Toxicol. Appl. Pharmacol.* 95:12-23, 1988.
18. Kerger BD, Roberts SM, Hinson JA, Gandy J, Harbison RD, and James RC: Antagonism of bromobenzene-induced hepatotoxicity by phentolamine: Evidence for a metabolism independent intervention. *Toxicol. Appl. Pharmacol.* 95:24-31, 1988.
19. James RC, Wessinger WD, Roberts SM, Millner GC, and Paule MG: Centrally mediated opioid induced depression of hepatic glutathione: Effects of intracerebroventricular administration of *mu*, *kappa*, *sigma*, and *delta* agonists. *Toxicology* 51:267-279, 1988.
20. Kerger BD, Roberts SM, and James RC: Comparison of human and mouse liver metabolism of bromobenzene and chlorobenzene to 2- and 4-halophenols. *Drug Metab. Dispos.* 16:672-677, 1988.
21. Smith AC, Roberts SM, James RC, Berman LM, and Harbison RD: Comparison of covalent binding from halothane metabolism in hepatic microsomes from phenobarbital-induced and hyperthyroid rats. *Xenobiotica* 18:991-1001, 1988.
22. Kerger BD, Roberts SM, Harbison RD, and James RC: Antagonism of bromobenzene-induced hepatotoxicity by the α -adrenoreceptor blocking agents phentolamine and idazoxan: Role of hypothermia. *Toxicol. Appl. Pharmacol.* 97:360-369, 1989.
23. Skoulis NP, James RC, Harbison RD, and Roberts SM: Depression of hepatic glutathione by opioid analgesic drugs in mice. *Toxicol. Appl. Pharmacol.* 99:139-147, 1989.
24. Roberts SM, Adams LE, Donovan-Brand R, Budinsky RA, Skoulis NP, Zimmer HW, and Hess EV: Procainamide hydroxylamine lymphocyte toxicity -- I. Evidence for participation by hemoglobin. *Int. J. Immunopharmacol.* 11:419-427, 1989.
25. Clevenger MA, Roberts SM, Lattin DL, Harbison RD, and James RC: The pharmacokinetics of 2,2',5,5'-tetrachlorobiphenyl and 3,3',4,4'-tetrachlorobiphenyl and its relationship to toxicity. *Toxicol. Appl. Pharmacol.* 100:315-327, 1989.
26. Skoulis NP, James RC, Harbison RD, and Roberts SM: Perturbation of glutathione by a central action of morphine. *Toxicology* 57:287-302, 1989.
27. Adams LE, Sanders CE, Budinsky RA, Donovan-Brand R, Roberts SM, and Hess EV: Immunomodulatory effects of procainamide metabolites: Their implications in drug-related lupus. *J. Lab. Clin. Med.* 113:482-492, 1989.
28. Roberts SM, Pounds JG, and James RC: Cocaine toxicity in cultured rat hepatocytes. *Toxicology Letters* 50:283-288, 1990.
29. Simmons HF, James RC, Harbison RD, and Roberts SM: Depression of glutathione by cold-restraint in mice. *Toxicology* 61:59-71, 1990.
30. Adams LE, Roberts SM, Carter JM, Wheeler JF, Zimmer HW, Donovan-Brand RJ, and Hess EV: Effects of procainamide hydroxylamine on generation of reactive oxygen species by macrophages and production of cytokines. *Int. J. Immunopharmacol.* 12:809-819, 1990.
31. Simmons HF, James RC, Harbison RD, Patel DG, and Roberts SM: Examination of the role of catecholamines in hepatic glutathione suppression by cold-restraint in mice. *Toxicology* 67:29-40, 1991.

32. Wheeler JF, Adams L, Mongey A-B, Roberts SM, Heineman WR, and Hess EV: Determination of metabolically-derived nitroprocainamide in the urine of procainamide-dosed humans and rats by liquid chromatography with electrochemical detection. *Drug Metab. Dispos.* 19:691-695, 1991.
33. Roberts SM, Harbison RD, and James RC: Human microsomal *N*-oxidative metabolism of cocaine. *Drug Metab. Dispos.* 19:1046-1051, 1991.
34. Harbison RD, James RC, and Roberts SM: Hepatic glutathione suppression by the α -adrenoreceptor stimulating agents phenylephrine and clonidine. *Toxicology* 69:279-290, 1991.
35. Roberts SM, Harbison RD, Seng JE, and James RC: Potentiation of carbon tetrachloride hepatotoxicity by phenylpropanolamine. *Toxicol. Appl. Pharmacol.* 111:175-188, 1991.
36. Roberts SM, Munson JW, James RC, and Harbison RD: An assay for cocaethylene and other cocaine metabolites in liver using high performance liquid chromatography. *Anal. Biochem.* 202:256-261, 1992.
37. Roth L, Harbison RD, James RC, Tobin T, and Roberts SM: Cocaine hepatotoxicity: Influence of hepatic enzyme inducing and inhibiting agents on the site of necrosis. *Hepatology* 15:934-940, 1992.
38. Roberts SM, Roth L, Harbison RD, and James RC: Cocaethylene hepatotoxicity in mice. *Biochem. Pharmacol.* 43:1989-1995, 1992.
39. James RC, Harbison RD, and Roberts SM: Phenylpropanolamine potentiation of acetaminophen-induced hepatotoxicity: Evidence for a glutathione-dependent mechanism. *Toxicol. Appl. Pharmacol.* 118:159-168, 1993.
40. James RC, Busch H, Tamburro CH, Roberts SM, Schell JG, and Harbison RD: Polychlorinated biphenyl exposure and human disease. *J. Occup. Med.* 35:136-148, 1993.
41. Adams LE, Balakrishnan K, Roberts SM, Belcher R, Mongey A-B, Thomas TJ, and Hess EV: Genetic, immunologic and biotransformation studies of patients on procainamide. *Lupus* 2:89-98, 1993.
42. Roberts SM, Harbison RD, and James RC: Inhibition by ethanol of the metabolism of cocaine to benzoylecgonine and ecgonine methyl ester in mouse and human liver. *Drug Metab. Dispos.* 21:537-541, 1993.
43. Adams LE, Roberts SM, Donovan-Brand R, Zimmer H, and Hess EV: Study of procainamide hapten-specific antibodies in rabbits and humans. *Int. J. of Immunopharmacology* 15:887-897, 1993.
44. Roberts SM, Harbison RD, Roth L, and James RC: Methylphenidate-induced hepatotoxicity in mice and its potentiation by β -adrenergic agonist drugs. *Life Sci.* 55:269-281, 1994.
45. James RC, Roberts SM, and Williams PL: An evaluation of the adequacy of the Threshold Limit Value (TLV) for cyclonite (RDX). *Appl. Occup. Environ. Hyg.* 9:485-492, 1994.
46. Roberts SM, Harbison RD, and James RC: Methamphetamine potentiation of carbon tetrachloride hepatotoxicity in mice. *J. Pharmacol. Exp. Ther.* 271:1051-1057, 1994.
47. Williams CA, Jones HD, Freeman RW, Wernke MJ, Williams PL, Roberts SM, and James RC: The EPC approach to estimating safety from exposure to environmental chemicals. *Reg. Toxicol. Pharmacol.* 20:259-280, 1994.

48. Roberts SM, Harbison RD, Westhouse RA, and James RC: Exacerbation of carbon tetrachloride-induced liver injury in the rat by methamphetamine. *Toxicol. Lett.* 76:77-83, 1995.
49. Roberts SM, Harbison RD, and James RC: Mechanistic studies on the potentiation of carbon tetrachloride hepatotoxicity by methamphetamine. *Toxicology* 97:49-57, 1995.
50. Roberts SM, Phillips DL, and Tebbett IR: Increased blood and brain cocaine concentrations with ethanol cotreatment in mice. *Drug Metab. Dispos* 23:664-666, 1995.
51. Borgert CJ, Roberts SM, Harbison RD, and James RC: Influence of soil half-life on risk assessment of carcinogens. *Reg. Pharmacol. Toxicol.* 22:143-151, 1995.
52. Salminen WF, Voellmy R, and Roberts SM: Induction of hsp70 in HepG2 cells in response to hepatotoxicants. *Toxicol. Appl. Pharmacol.* 141:117-123, 1996.
53. Roberts SM, DeMott R, and James RC: Adrenergic modulation of hepatotoxicity. *Drug Metab. Rev.* 29:329-353, 1997.
54. Salminen WF, Roberts SM, Fenna M, and Voellmy RM: Heat shock protein induction in murine liver after acute treatment with cocaine. *Hepatology* 25:1147-1153, 1997.
55. Salminen WF, Voellmy RM, and Roberts SM: Differential heat shock protein induction by acetaminophen and a non-hepatotoxic regioisomer, 3'-hydroxyacetanilide, in mouse liver. *J. Pharmacol. Exp. Ther.* 282:1533-1540, 1997.
56. Salminen WF, Voellmy R, and Roberts SM: Protection against hepatotoxicity by a single dose of amphetamine: The potential role of heat shock protein induction. *Toxicol. Appl. Pharmacol.* 147:247-258, 1997.
57. Calabrese EJ, Stanek EJ, James RC, and Roberts SM: Soil ingestion: A concern for acute toxicity in children. *Environ. Health Perspect.* 105:1354-1358, 1997.
58. Ndikum-Moffor FM, Schoeb TR, and Roberts SM: Liver toxicity from norcocaine nitroxide, an N-oxidative metabolite of cocaine. *J. Pharmacol. Exp. Ther.* 284:413-419, 1998.
59. Salminen WF, Roberts SM, Pumford NR, and Hinson JA: Immunochemical comparison of 3'-hydroxyacetanilide and acetaminophen binding in mouse liver. *Drug Metab. Dispos.* 26:267-27, 1998.
60. Ndikum-Moffor FM, Munson JW, Bokinkere NK, Brown JL, Richards N, and Roberts SM: Immunochemical detection of hepatic cocaine-protein adducts in mice. *Chem. Res. Toxicol.* 11:185-192, 1998.
61. Tonner-Navarro LE, Phelps JL, Roberts SM, and Teaf CM: Current risk assessment approaches to address petroleum hydrocarbon mixtures in soils. *Human Ecol. Risk Assess.* 4:721-736, 1998.
62. Zou J, Salminen WF, Roberts SM, and Voellmy R: Correlation between stress induction of the hsp response, glutathione oxidation, and heat shock factor activation. *Cell Stress & Chaperones* 3:130-141, 1998
63. Salminen WF, Voellmy R, and Roberts SM: Effect of N-acetylcysteine on heat shock protein induction by acetaminophen in mouse liver. *J. Pharmacol. Exp. Ther.* 286:519-524, 1998.

64. Abernathy CO and Roberts SM: Some uncertainties in the arsenic human health risk assessment. *Human Ecol. Risk Assess.* 4:1045-1049, 1998.
65. Roberts SM: The utility of toxic equivalency factors (TEFs) in human and ecological risk assessment. *Human Ecol. Risk Assess.* 5:7-8, 1999.
66. Roberts SM: Practical issues in the use of probabilistic risk assessment. *Human Ecol. Risk Assess.* 5:729-736, 1999.
67. Marsella R, Nicklin CF, Munson J, and Roberts SM: Pharmacokinetics of pentoxifylline in dogs after oral and intravenous administration. *Amer. J. Vet. Res.* 61:631-637, 2000.
68. Boess F, Ndikum-Moffor FM, Boelsterli UA, and Roberts SM: Effects of cocaine and its oxidative metabolites on mitochondrial respiration and generation of reactive oxygen species. *Biochem. Pharmacol.* 60:615-623, 2000.
69. Halmes NC, Roberts SM, Tolson JK, and Portier CJ: Re-evaluating cancer risk estimates for short-term exposure scenarios. *Tox. Sci.* 58:32-42, 2000.
70. Roberts SM: Environmental Justice: Examining the role of risk assessment. *Human Ecol. Risk Assess.* 6:537-540, 2000.
71. Rojas M, Drake PL, and Roberts SM: Assessing mercury health effects in gold workers near El Callao, Venezuela. *J. Occup. Env. Med.* 43:158-165, 2001.
72. Roberts SM: Another view of the scientific foundations of hormesis. *Crit. Rev. Toxicol.* 31:631-635, 2001.
73. Roberts SM: Ethical issues in the use of data from testing of human subjects to support risk assessment. *Human Ecol. Risk Assess.* 7:1569-1573, 2001.
74. Roberts SM, Jordan KE, Warren DA, Britt JK, and James RC: Evaluation of the carcinogenicity of 1,1-dichloroethylene (vinylidene chloride). *Reg. Toxicol. Pharmacol.* 35:44-55, 2002.
75. Roberts SM, Weimar WR, Vinson JRT, Munson JW, and Bergeron RJ: Measurement of arsenic bioavailability in soil using a primate model. *Tox. Sci.* 67:303-310, 2002.
76. Ndikum-Moffor FM and Roberts SM: Cocaine-protein targets in mouse liver. *Biochem. Pharmacol.* 66:105-113, 2003.
77. Roberts SM: Incorporating information on bioavailability of soil-borne chemicals into human health risk assessments. *Human Ecol. Risk Assess.* 10: 631-635, 2004.
78. Tolson JK and Roberts SM: Manipulating heat shock protein expression in laboratory animals. *Methods* 35:149-157, 2005.
79. Tolson JK, Roberts SM, Jortner B, Pomeroy M, and Barber DS: Heat shock proteins and acquired resistance to uranium nephrotoxicity. *Toxicology* 206:59-73, 2005.
80. Sobel ES, Gianini J, Butfiloski EJ, Croker BP, Schiffenbauer J, and Roberts SM: Acceleration of autoimmunity by organochlorine pesticides in (NZBxNZW)F1 mice. *Environ. Health Perspect.* 113:323-328, 2005.
81. Vilaboa N, Fenna M, Munson J, Roberts SM, and Voellmy R: Novel gene switches for targeted and timed expression of therapeutic proteins. *Mol. Ther.* 12:290-298, 2005.

82. Sobel ES, Wang F, Butfiloski E, Croker B, and Roberts SM: Comparison of chlordecone effects on autoimmunity in (NZBxNZW)F1 and BALB/c mice. *Toxicology* 218:81-89, 2006.
83. Tolson JK, Dix DJ, Voellmy RW, and Roberts SM: Increased hepatotoxicity of acetaminophen in Hsp70i knockout mice. *Toxicol. Appl. Pharmacol.* 210:157-162, 2006.
84. Powers KW, Brown SC, Krishna VB, Wasdo SC, Moudgil BM, and Roberts SM: Research strategies for safety evaluation of nanomaterials, Part VI: Characterization of nanoscale particles for toxicological evaluation. *Tox. Sci.* 90:296-303, 2006.
85. Portier K, Tolson JK, and Roberts SM: Body weight distributions for risk assessment. *Risk Anal.* 27:11-26, 2007.
86. Roberts SM, Munson JW, Lowney YW, and Ruby MV: Relative oral bioavailability of arsenic from contaminated soils measured in the cynomolgus monkey. *Tox. Sci.* 95:281-288, 2007.
87. Powers KW, Palazuelos M, Moudgil BM, and Roberts SM: Characterization of the size, shape, and state of dispersion of nanoparticles for toxicological studies. *Nanotoxicology* 1:42-51, 2007.
88. Wang F, Roberts SM, Butfiloski EJ, Morel L, and Sobel ES: Acceleration of autoimmunity by organochlorine pesticides: A comparison of splenic B cell effects of chlordecone and estradiol in (NZBxNZW)F1 mice. *Tox. Sci.* 99:141-152, 2007.
89. Wang F, Roberts SM, Butfiloski EJ, and Sobel ES: Diminished prolactin from chlordecone treatment in ovariectomized (NZB x NZW)F₁ mice. *Int. Immunopharmacol.* 7:1808-1812, 2007.
90. Jimenez JJ, Roberts SM, Mejia J, Mauro LM, Munson JW, Elgart GW, Connelly EA, Chen Qu, Zou J, Goldenberg C, and Voellmy R: Prevention of chemotherapy-induced alopecia in rodent models. *Cell Stress Chap.* 13:31-38, 2008
91. Wasdo SC, Barber DS, Denslow ND, Powers KW, Palazuelos M, Stevens SM, Moudgil B, Roberts SM: Differential binding of serum proteins to nanoparticles. *Int. J. Nanotechnol.* 5:92-115, 2008.
92. Wang F, Sobel ES, Butfiloski EJ, and Roberts SM: Comparison of chlordecone and estradiol effects on splenic T-cells in (NZB x NZW) F1 mice. *Toxicol. Lett.* 183:1-9, 2008.
93. Brown SC, Palazuelos M, Sharma P, Powers KW, Roberts SM, Grobmeyer SR, Moudgil BM: Nanoparticle characterization for cancer nanotechnology and other biological applications. *Methods Mol. Biol.* 624:39-65, 2010.
93. Gadagbui B, Maier A, Dourson M, Parker A, Willis A, Christopher JP, Hicks L, Ramasamy S, Roberts SM: Derived reference doses (RfDs) for the environmental degradates of the herbicides alachlor and acetachlor: Results of an independent expert panel deliberation. *Reg. Toxicol. Pharmacol.* 57:220-234, 2010.
94. Stuchal LD, Weil RE, Roberts SM: Derivation of a chronic reference concentration for decalin. *Reg. Toxicol. Pharmacol.* (in press)

BOOK CHAPTERS

1. Roberts SM, James RC, and Harbison RD: Cocaine-induced hepatotoxicity, In *Cocaine: Pharmacology, Physiology and Clinical Strategies* (JM Lakosky, MP Galloway, and FP White, Eds), CRC Press, Boca Raton, 1992, pp. 15-33.

2. Borgert CM, Roberts SM, James RC, and Harbison RD: Perspectives on assessment of risks from dermal exposure to polycyclic aromatic hydrocarbons, In *Health Risk Assessment. Dermal and Inhalation Exposure and Absorption of Toxicants* (R Wang, J.B. Knaak, and H.I. Maibach, Eds), CRC Press Boca Raton, 1993, pp 455-470.
3. James RC, Roberts SM, and Williams PL: General principles of toxicology. In *Principles of Toxicology: Environmental and Industrial Applications*, PL Williams, RC James, and SM Roberts, Eds, John Wiley & Sons, New York, 2000, pp. 3-34.
4. Roberts SM, James RC, and Franklin MR: Hepatotoxicity: Toxic effects on the liver. In *Principles of Toxicology: Environmental and Industrial Applications*, PL Williams, RC James, and SM Roberts, Eds, John Wiley & Sons, New York, 2000, pp. 111-128.
5. Salminen WR and Roberts SM: Dermal and ocular toxicology: Toxic effects of the skin and eyes. In *Principles of Toxicology: Environmental and Industrial Applications*, PL Williams, RC James, and SM Roberts, Eds, John Wiley & Sons, New York, 2000, pp. 157-168.
6. Roberts SM and Adams L: Immunotoxicity: Toxic effects on the immune system. In *Principles of Toxicology: Environmental and Industrial Applications*, PL Williams, RC James, and SM Roberts, Eds, John Wiley & Sons, New York, 2000, pp. 189-206.
7. James RC, Warren A, Halmes NC, and Roberts SM: Risk assessment. In *Principles of Toxicology: Environmental and Industrial Applications*, PL Williams, RC James, and SM Roberts, Eds, John Wiley & Sons, New York, 2000, pp. 437-478.
8. Ochoa-Acuna HG and Roberts SM: Children exposed to playsets treated with chromated copper arsenate: A review of risk assessment approaches. In *Environmental Impacts of Preservative-Treated Wood*, T Townsend and H Solo-Gabriel, Eds., Taylor and Frances Publishers, New York, 2006.
9. Stuchal LD and Roberts SM: Risk assessment of chemicals. In *General and Applied Toxicology*, Third Edition, B Ballantyne, TC Marrs, T Syversen, Eds., John Wiley & Sons, West Sussex, UK, 2009, pp. 2655-2680.
10. Powers KW, Palazuelos M, Brown SC, and Roberts SM: Characterization of nanomaterials for toxicological evaluation. In, *Nanotoxicity: From In Vivo and In Vitro Models to Health Risks*, S Sahu and DA Casciano, Eds, Wiley, New York, 2009, pp. 1-28.
11. Hinkley GK and Roberts SM: Particle and fiber toxicology. In, *Particular Products: Design Properties and Performance Optimization*. H. Merkus, Ed, Springer, 2013 (in press)

BOOKS EDITED:

1. *Hazardous Waste Incineration: Evaluating the Human Health and Environmental Risks*, SM Roberts, CM Teaf, and JA Bean, Eds., Lewis Publishers, Boca Raton, FL, 1999.
2. *Principles of Toxicology: Environmental and Industrial Applications*, PL Williams, RC James, and SM Roberts, Eds, John Wiley & Sons, New York, 2000.

PUBLISHED ABSTRACTS, LETTERS, ETC.:

1. Roberts SM and Franklin MR: Propoxyphene and *in vivo* formation of cytochrome P-450 metabolic intermediate complexes. *Pharmacologist* 18:210, 1976
2. Franklin MR and Roberts SM: The cytochrome P-450 dependent metabolism of drugs of possible use in opiate addiction treatment programs. *Fed. Proc.* 36:940, 1977
3. Roberts SM and Franklin MR: Isolated rat hepatocytes and cytochrome P-450 metabolic intermediate complexes. *Fed. Proc.* 37:464, 1978
4. Galinsky RE and Roberts SM: Comments on constant blood withdrawal method for obtaining AUC. *Drug Intell. Clin. Pharm.* 13:81, 1980
5. James RC, Roberts SM, and Harbison RD: Depletion of mouse hepatic glutathione by selected endogenous compounds. *Toxicologist* 2:183, 1982
6. Roberts SM, Grund VR, James RC, and Harbison RD: Examination of the potential role of histamine in morphine-induced hepatic glutathione depletion. *Toxicologist* 2:191, 1982
7. Parrott CL, Hirsch CS, Zumwalt RE, and Roberts SM: Fatal acetaminophen-induced liver injury. *Forensic Pathol.* 24(2):1, 1982
8. Budinsky RA, Roberts SM, Adams LE, Litwin A, and Hess EV: Acetylation of procainamide in strains of mouse, rat, and guinea pig. *Fed. Proc.* 43:560, 1984
9. Roberts SM, Myre SA, Hunter RH, Fant WK, and Coats EA: Computer-assisted instruction in pharmacy. *Amer. J. Pharm. Ed.* 48:76, 1984
10. Roberts SM, Skoulis NP, and James RC: A central effect of morphine to diminish hepatocellular glutathione. *Fed. Proc.* 44:501, 1985
11. Budinsky RA, Roberts SM, Coats EA, Adams LE, and Hess EV: The formation of procainamide hydroxylamine by rat and human liver microsomes. *Toxicologist* 6:250, 1986
12. Budinsky RA, Roberts SM, Coats EA, Adams LE, and Hess EV: Partial characterization of procainamide hydroxylamine formation by rat liver microsomes. *Fed. Proc.* 1986
13. Kerger BD, Hinson JA, Harbison RD, Roberts SM, Gandy J, and James RC: Antagonism of bromobenzene-induced hepatotoxicity: Evidence for a pharmacological intervention by phentolamine. *Pharmacologist* 29:148, 1987
14. Skoulis, NP, James RC, Harbison RD, and Roberts SM: Depression of hepatic glutathione by opioid analgesic drugs in mice. *Toxicologist* 8:234, 1988
15. Smith MA, Gandy J, Roberts SM, James RC, and Harbison RD: Phentolamine antagonism of iodobenzene hepatotoxicity in B6C3F1 mice. *Toxicologist* 9:60, 1989.
16. Skoulis NP, James RC, Harbison RD, and Roberts, SM: Morphine-induced depression of hepatic glutathione: Relationship to hypoxia, hypothermia, tolerance, and glutathione status in other tissues. *Toxicologist* 9:169, 1989.
17. Simmons HF, James RC, Harbison RD, and Roberts, SM: Diminished glutathione in mice subjected to cold-restraint stress. *Toxicologist* 9:169, 1989.

18. Seng JE, James RC, Harbison RD, and Roberts SM: Glutathione depletion and potentiation of carbon tetrachloride hepatotoxicity by sympathomimetic amines. *Toxicologist* 9:170, 1989.
19. Roberts SM, James RC, and Harbison RD: Potentiation of acetaminophen hepatotoxicity by phenylpropanolamine. *Toxicologist* 10:200, 1990.
20. Adams, LE, Wheeler JF, Roberts SM, Donovan-Brand R, Zimmer H, Carter, JM, and Hess EV: In vitro effects of procainamide metabolites on superoxide and cytokine production by murine splenic cells. *FASEB J.* 4:A1767.
21. James RC, Harbison RD, and Roberts SM: Hepatic glutathione suppression by the selective α -adrenergic receptor agonists clonidine and phenylephrine. *Toxicologist* 11:53, 1991.
22. Roberts SM, Roth L, James RC, and Harbison RD: Altering liver metabolism shifts the intralobular site of cocaine-induced injury. *Toxicologist* 11:171, 1991.
23. James RC, Harbison RD, Roth L, and Roberts SM: Hepatotoxicity of methylphenidate: Potentiation by beta-adrenoreceptor stimulating compounds. *Toxicologist* 12:65, 1992.
24. Roth L, Harbison RD, James RC, Tobin T, and Roberts SM: Localization of cocaine and metabolites in liver sections: Effect of enzyme inducer pretreatment. *Toxicologist* 12:66, 1992.
25. Roberts SM, Roth L, James RC, and Harbison RD: Cocaethylene: Comparison of liver toxicity with its parent compound, cocaine. *Toxicologist* 12:66, 1992.
26. James RC, Harbison RD, and Roberts SM: Methamphetamine potentiation of carbon tetrachloride hepatotoxicity. *Toxicologist* 13:340, 1993.
27. Roberts SM, Harbison RD, and James RC: Ethanol inhibition of cocaine esteratic metabolism. *Toxicologist* 13:386, 1993.
28. Westhouse RA, James RC, Harbison RD, and Roberts SM: Adrenergic effects on the proliferation rate of tumor cells in chemically induced mouse hepatocellular adenomas. *Toxicologist* 14:128, 1994.
29. Voellmy RM, Salminen WF, Borgert CJ, Westhouse RA, James RC, Harbison RD, and Roberts SM: Measurement of changes in liver levels of stress proteins following administration of selected hepatotoxicants in the mouse. *Toxicologist* 14:133, 1994.
30. Borgert CJ, Roberts SM, Harbison RD, and James RC: Effect of soil half-life on risk assessment of carcinogens. *Toxicologist* 14:154, 1994.
31. DeMott RP, James RC, Roberts SM, and Harbison RD: Antagonism of bromobenzene-induced hepatotoxicity following delayed administration of phentolamine. *Toxicologist* 14:192, 1994.
32. James RC, Harbison RD, and Roberts SM: Methamphetamine potentiation of carbon tetrachloride hepatotoxicity: Evaluation of possible mechanisms. *Toxicologist* 14:274, 1994.
33. Rousseau SG and Roberts SM: Metabolism of cocaine in vitro in second trimester human fetal liver. *Toxicologist* 14:283, 1994.
34. Cook ML, Westhouse RA, James RC, Harbison RD, and Roberts SM: Methamphetamine potentiation of carbon tetrachloride hepatotoxicity: Examination of suppression of early cell replication as a possible mechanism. *Toxicologist* 14:374, 1994.

35. Peris J, Roberts SM, Phillips D and Tebbett I: Chronic ethanol exposure increases serum cocaine levels in rats. *Alcoholism: Clin. Exp. Res.* 18:522, 1994.
36. Williams P, James R, and Roberts S: An evaluation of the adequacy of the threshold limit value for cyclonite. *American Industrial Hygiene Conference & Exposition Abstracts* 146:32, 1994.
37. Salminen WF, Voellmy RM, James RC, Harbison RD, and Roberts SM: HSP70 induction in HepG2 cells in response to hepatotoxicants. *Toxicologist* 15:49, 1995.
38. James RC, Schell JD, Roberts SM, Price B, and Freeman RW: Using human data to develop better cancer slope factors: PCBs as an example. *Toxicologist* 15:88, 1995.
39. Harbison RD, James RC, and Roberts SM: Morphine potentiation of carbon tetrachloride hepatotoxicity in mice. *Toxicologist* 15:220, 1995.
40. DeMott RP, James RC, Westhouse RA, Roberts SM, and Harbison RD: Nephrotoxicity of 2-bromoquinone can be reduced by the adrenergic antagonist phentolamine. *Toxicologist* 15:300, 1995.
41. Roberts SM, Voellmy RM, and Salminen WF: Immunohistochemical localization of hsp 25 and hsp 70 induction in murine liver after acute treatment with carbon tetrachloride or bromobenzene. *Fund. Applied Tox. (Suppl.)* 30:82, 1996.
42. Rousseau SG and Roberts SM: Ethanol-enhanced cocaine hepatotoxicity in mice: Examination of the role of norcoethylen. *Fund. Applied Tox. (Suppl.)* 30:76, 1996.
43. Salminen WF, Voellmy RM, and Roberts SM: Heat shock protein induction in murine liver after acute treatment with cocaine. *Fund. Applied Tox. (Suppl.)* 30:77, 1996.
44. Tolson JK, Roberson GA, and Roberts SM: Improving estimates of risk for workers exposed to contaminated soils at agricultural sites. *Fund. Applied Tox. (Suppl.)* 30:146, 1996.
45. Harbison RD, Gill J, Roberts SM, and DeMott RP: Reevaluation of adrenoreceptor mediated hepatoprotection from bromobenzene. *Fund. Applied Tox. (Suppl.)* 30:290, 1996.
46. Ndikum-Moffor FM and Roberts SM: Identification of target proteins in mouse liver following an hepatotoxic dose of cocaine. *Fund. Appl. Tox. (Suppl.)* 36:211, 1997.
47. Salminen WF, Voellmy RM, and Roberts SM: Heat shock protein induction by amphetamine in mice: Effect on hepatotoxicity of acetaminophen, bromobenzene, cocaine, and carbon tetrachloride. *Fund. Appl. Tox. (Suppl.)* 36:211, 1997.
48. Roberts SM and Ndikum-Moffor FM: Norcocaine nitroxide hepatotoxicity in mice. *Fund. Appl. Tox. (Suppl.)* 36:211, 1997.
49. Halmes NC, Tonner-Navarro LE, Portier K, James RC, and Roberts SM: An analysis of the risk impact associated with changes in surface water standards in Florida. *Toxicol. Sci.* 42:60, 1998.
50. Tonner-Navarro LE, Halmes NC, Sielken RL, James RC, and Roberts SM: Estimating cancer risks from dermal exposure to benzo(a)pyrene. *Toxicol. Sci.* 42:225, 1998.
51. Roberts SM, Salminen WF, and Voellmy R: N-Acetylcysteine effects on heat shock protein induction by acetaminophen in mouse liver. *Toxicol. Sci.* 42:362, 1998.

52. Ndikum-Moffor FM and Roberts SM: Characterization and distribution of cocaine-protein adducts in mouse liver fractions. *Toxicol. Sci.* 42:364, 1998.
53. Tolson JK, Voellmy RM, and Roberts SM: Transgenic mouse model for hepatic expression of the 27kDa human heat shock protein (HSP27). *Toxicol. Sci.* 42:372, 1998.
54. Halmes NC, Tolson JK, Portier CJ, and Roberts SM: Re-evaluating cancer risk estimates for short-term exposure scenarios. *Toxicol. Sci.* 48:81, 1999.
55. Saranko CJ, Sielken RL, Guzelian PS, James RC, and Roberts SM: Development of inhalation and oral benchmark doses for trichloroethylene based on carcinogenicity in mice. *Toxicol. Sci.* 48:83, 1999.
56. Ndikum-Moffor FM and Roberts SM: Cocaine-protein adducts in mouse liver: Comparison of detection by radiochemical and immunochemical methods. *Toxicol. Sci.* 48:196, 1999.
57. Tolson JK and Roberts SM: Cytoprotection from thioacetamide-induced liver injury associated with heat shock protein induction. *Toxicol. Sci.* 48:196, 1999.
58. Roberts SM and Schiffenbauer J: Acceleration of autoimmunity by three chlorinated pesticides with estrogenic effects. *Toxicol. Sci.* 48:317, 1999.
59. Tolson JK, Voellmy RM, and Roberts SM: Overexpression of heat shock proteins in HepG2 cells using adenoviral gene delivery. *Toxicol. Sci.* 54:42, 2000.
60. Ramaiah SK, Munson JW, Tolson JK, and Roberts SM: Protein adduct formation by norcocaine nitroxide, an N-oxidative metabolite of cocaine. *Toxicol. Sci.* 54:45, 2000.
61. Ramaiah SK, Munson JW and Roberts SM: Identification of cocaine hepatic protein targets in vivo using 2D gel electrophoresis and mass spectrometry. *Toxicol. Sci.* 60:119, 2001.
62. Tolson JK, Voellmy R, and Roberts SM: Cytoprotection afforded by specific upregulation of hsp27 or hsp70I in HepG2 cells. *Toxicol. Sci.* 60:345, 2001.
63. Ochoa-Acuna HG, Sepulveda MS, Gross TS, and Roberts SM: Mercury in feathers from birds of the Southeastern Pacific: Influence of location and taxonomic affiliation. *Toxicol. Sci.* 60:357, 2001.
64. Roberts SM, Weiman WR, Vinson JR, Munson JW, and Bergeron RJ: Measurement of arsenic bioavailability from soils using a primate model. *Toxicol. Sci.* 60:436, 2001.
65. Jordan KE, Britt JK, Halmes NC, James RC, Warren DA, and Roberts SM: Evaluation of the carcinogenicity of 1,1-dichloroethylene (vinylidene chloride) and development of inhalation and oral benchmark doses. *Toxicol. Sci.* 60:439, 2001.
66. Rojas M, Drake PL, and Roberts SM: Assessing mercury health effects in gold workers near El Callao, Venezuela. *Toxicology* 164:62-63, 2001.
67. Roy S, Ochoa HG, Tolson JK, Harris WG, and Roberts SM: Volatilization of chemicals from groundwater into indoor air. *Toxicol. Sci.* 66(1-S):17, 2002.
68. Ochoa-Acuna H, Tolson JK, and Roberts SM: Dermal exposure to contaminants while swimming: An assessment of the risks and hazards associated with USEPA Ambient Water Quality Criteria. *Toxicol. Sci.* 66(1-S): 102, 2002.

69. Tolson JK, Dix DJ, Voellmy RW, and Roberts SM: Increased hepatotoxicity of acetaminophen in hsp 70k knockout mice. *Toxicol. Sci.* 72(S-1): 196, 2003.
70. Munson JW, Tolson JK, Jortner BS, Roberts SM, and Barber DS: Heat shock proteins and uranium nephrotoxicity. *Toxicol. Sci.* 72(S-1): 347, 2003.
71. Roberts SM and Sobel E: Acceleration of the development of lupus in NZBxNZWF1 mice by chlordecone. *Toxicol. Sci.* 72(S-1): 373, 2003.
72. Roy S, Tolson JK, Portier KM, and Roberts SM: Beefing up — Revised body weights and skin surface area estimates. *Toxicol. Sci.* 72(S-1): 389, 2003.
73. Ochoa-Acuna H and Roberts SM: An estimation of cancer risks posed by exposure to particulate matter in air in Santiago, Chile. *Toxicol. Sci.* 72(S-1): 393, 2003.
74. Saranko CJ, Mills CE, Tolson JK, Roberts SM, and Portier KM: The effect of censored data on the performance of techniques for calculating 95% upper confidence limits (95% UCL) on the mean. *Toxicol. Sci.* 72(S-1): 395, 2003.
75. Mills CE, Saranko CJ, Tolson JK, Roberts SM, and Portier KM: Comparison of techniques for calculating 95% upper confidence limits (95% UCLs) on the mean. *Toxicol. Sci.* 72(S-1): 395, 2003.
76. Gadagbui BK, Pounds JG, Simon TW, and Roberts SM: A soil concentration limit for lead based on acute exposure in children. *Toxicol. Sci.* 72(S-1): 396, 2003.
77. Ochoa Acuña, H. and S.M. Roberts. Development of default alternative screening values for soil and sediment based on protection to wildlife. Society of Toxicology 43rd Annual Meeting, Baltimore, MD. 2004.
78. Szabo NJ, Wasdo SC, Brubaker G, Jenkins CM, and Roberts SM: Dissolution rates of nanoparticulate metallic species in artificial human sweat under physiologically relevant conditions. *Toxicol. Sci.* 84(S-1), 2005.
79. Wang F, Roberts SM, and Sobel ES: Comparison of chlordecone and estrogen effects on phenotypic markers on immunocytes. *Toxicol. Sci.* 84(S-1), 2005.
80. Tufariello EM, Saranko CM, Ettinger R, Roberts SM, and Tolson K: Development of Florida-specific risk-based soil and groundwater cleanup targets for volatilization of chemicals into indoor air. *Toxicol. Sci.* 84(S-1), 2005.
81. Tolson JK, Saranko CJ, Roberts SM, and Portier, KM: A robust algorithm for calculating optimal 95% upper confidence limits (95% UCLs) on the mean for environmental datasets. *Toxicol. Sci.* 84(S-1), 2005.
82. Wasdo SC, Roberts SM, Santra S, Munson J, and Song Y: Imaging the penetration of rubpy-doped silica nanoparticles into human and mouse skin with fluorescent microscopy. *Toxicol. Sci.* 84(S-1), 2005.
83. Roberts SM: Assessing dermal penetration of nanomaterials by light and electron microscopy. *Toxicol. Sci.* 90(S-1), 2006.
84. Lowney Y, Ruby MV, Peterson LA, and Roberts SM: Progress toward development of in vitro methods for assessing the relative oral bioavailability of arsenic from soil. *Toxicol. Sci.* 90(S-1), 2006.

85. Roberts SM, Munson JW, Lowney Y, and Ruby MV: Measurement of the relative bioavailability of arsenic from soil in cynomolgus monkeys. *Toxicol. Sci.* 90(S-1), 2006.
86. Dutta D, Santra S, Roberts SM, and Moudgil BM: Assessing the in vitro toxicity of functionalized amorphous silica nanoparticles. *Toxicol. Sci.* 90(S-1), 2006.
87. Saranko CJ, Tolson JK, Budinsky R, Landenberger B, Roberts SM, and Portier KM: Statistical methods for handling censored dioxin/furan congener data. *Toxicol. Sci.* 90(S-1), 2006.
88. Wang F and Roberts SM: Examination of a potential estrogenic mode of action for chlordecone acceleration of autoimmunity in NZBxNZW/F1 mice. *Toxicol. Sci.* 90(S-1), 2006.
89. Lowney YW, Roberts S, Wester R, and Ruby M: Oral bioavailability and dermal absorption of arsenic from soil: In vivo research and progress towards in vitro methods. *Epidemiology* 17:S461, 2006.
90. Freeman N, Schuck M, Finch Z, Economos E, Roberts S, and Flocks J: Assessment of resident's environmental health perceptions. *Epidemiology* 17:S451, 2006.
91. Roberts SM: The future of hazard identification. *Toxicol. Sci.* (S-1), 2007.
92. Wang F, Roberts SM, and Sobel ES: Evaluation of the effects of organochlorine pesticides on macrophage functions. *Toxicol. Sci.* (S-1), 2007.
93. Wasdo SC, Roberts SM, Barber DS, Powers KW, and Palazuelos M: The preferential binding of human serum proteins to Ni, Al, and diamond nanoparticles. *Toxicol. Sci.* (S-1), 2007.
94. Tolson JK, Saranko CJ, Schuck ME, and Roberts SM: Comparison of tools to calculate 95% upper confidence limits on the mean. *Toxicol. Sci.* (S-1), 2007.
95. Schuck ME, Goff K, Roberts SM, Tolson JK: Geospatial consideration in calculating 95% upper confidence limits on the mean. *Toxicol. Sci.* (S-1), 2008.
96. Roberts SM, Powers KW, Wasdo SC: Assessment of the dermal penetration and toxicity of nanoparticulate metals. *Toxicol. Sci.* (S-1), 2008.
97. James RC, Kerger BD, Roberts SM, Payer AF, Hehir DJ, DeCaprio AP: Higher polychlorinated biphenyl (PCB) levels and ratios in skin lipids relative to adjacent subcutaneous adipose lipids. *Toxicol. Sci.* (S-1), 2008.
98. Barber DS, Stevens S, Wasdo S, Feswick A, Carpinone P, Denslow N, Powers K, and Roberts SM: Nanoparticle size and composition affect adsorption of human plasma protein. *Toxicol. Sci.* (S-1), 2009.
99. Tolson K, P Goodrum, S Roberts, L Stuchal, C Saranko, A Singh, J Hathaway, K Black, L Mora-Applegate. Performance of Incremental Sampling Techniques for Estimation of Exposure Point Concentrations. Proceedings of the Society of Environmental Toxicology and Chemistry (SETAC) North America 30th Annual Meeting, New Orleans, LA: Abstract No. MP132, 2009.
100. Carpinone P, Munson J, Barber D, Siebein K, Powers K, and Roberts S: Differential sedimentation for the characterization of surface modified gold nanoparticles in whole blood. *Toxicol. Sci.* (S-1), 2010.

101. Roberts SM, Munson J, Lowney YW: Influence of phosphate on the bioavailability of arsenic from soil in cynomolgus monkeys. *Toxicol. Sci.* (S-1), 2010.
102. Hinkley GK, Barber D, Sharma P, Powers K, Roberts S: Uptake of silica nanoparticles and quantum dots in differentiated and undifferentiated THP-cells: An illustration of the challenges in measuring nanoparticle uptake by cells. *Toxicol. Sci.* (S-1), 2011.
103. Carpinone PL, Hinkley GK, Barber DS, Munson J, Powers KW, and Roberts SM: Differential interference with clinical chemistry assays by gold nanorods and gold and silica nanospheres. *Toxicol. Sci.* (S-1), 2011.
104. Carpinone PL, Powers KW, Barber DS, and Roberts SM: Protein adsorption behavior of PEG-coated gold nanoparticles in human plasma. *Tox Sci.* (S-1), 2012.
105. Hinkley G, Carpinone PL, Powers KW, Roberts SM: Oral bioavailability of gold nanoparticles in mice: PEG-coated vs. uncoated gold nanoparticles. *Tox. Sci.* (S-1), 2012.
106. Austin CA, Hinkley GK, Zhang Q, Umbreit TH, Betz MW, Brown KM, Francke-Carroll S, Hussain SM, Roberts SM, Goering PL: Distribution of intravenously-injected silver nanoparticles (AGNPS) in pregnant mice and developing embryos. *Tox. Sci.* (S-1), 2012.
107. Hinkley GK, Roberts SM, Powers KW: Correlating in vivo agglomeration state with oral bioavailability of gold nanoparticles. *Tox. Sci.* (S-1), 2013.
108. Weil RE, Stuchal LD, Kane AS, Roberts SM: Analysis of possible changes to the levels of concern for polycyclic aromatic hydrocarbons in seafood. *Tox. Sci.* (S-1), 2013.
109. Munson JW, Lowney YW, Ruby MV, Roberts SM: Estimating the relative bioavailability of polycyclic aromatic hydrocarbons (PAHs) from soil at environmentally-relevant concentrations. *Tox. Sci.* (S-1), 2013.
110. Stuchal LD, Weil RE, Roberts SM: Development of a chronic reference concentration for decalin. *Tox. Sci.* (S-1), 2013.